Merck's investigational medication enlicitide significantly decreased cholesterol levels in a large-scale study

By
Lauran Neergaard
February 4, 2026

Associated Press Health

Objective:

To evaluate the effectiveness of enlicitide in lowering LDL cholesterol in high-risk patients despite statin use.

Key Findings:

Enlicitide users experienced up to a 60% reduction in LDL cholesterol over six months.
The cholesterol-lowering effect persisted with only a slight decrease over one year.
No safety differences were observed between enlicitide and placebo groups.

Interpretation:

Enlicitide may provide a significant alternative to current cholesterol-lowering treatments, particularly for patients who do not achieve desired LDL levels with statins alone.

Limitations:

The long-term effects on heart attack and stroke rates are not yet established.
The pill must be taken on an empty stomach.

Conclusion:

If approved by the FDA, enlicitide could offer a more convenient oral option for managing high cholesterol in patients at risk for heart disease.

Merck's investigational medication enlicitide significantly decreased cholesterol levels in a large-scale study

Objective:

Key Findings:

Interpretation:

Limitations:

Conclusion:

Original Source(s)

Merck's experimental pill enlicitide sharply lowered cholesterol in a large study

Related Content

GCS May Expand CTRCD Assessment

A deep learning model based on combining surface and esophageal ECG data for diagnosis of paroxysmal supraventricular tachycardia

AI Scribes: Efficiency for Whom?